Variables | |||
---|---|---|---|
Age (years) | Range (mean ± SD) | 19–63 (36.82 ± 13.66) | |
F/M | No. (%) | 37 (74%)/13 (26%) | |
Disease duration (months) | Range (mean ± SD) | 3–12 (8.9 ± 3.09) | |
MS duration (min) range, | Range (mean ± SD) | 15–120 (44.2 ± 27.15) | |
SJC | Median (IQR) | 2 (2–3) | |
TJC | Median (IQR) | 2.5 (2–3) | |
pVAS (0–10) | Median (IQR) | 4 (3–5) | |
Extra-articular manifestation | (No, %) | 18 (36%) | |
HB (gm/dl) | Mean ± SD | 10.7 ± 1.2 | |
Platelet count (× 103/ul) | Mean ± SD | 268.4 ± 29.84 | |
ESR, mm/1st h | Mean ± SD | 40.26 ± 18.31 | |
CRP, mg/dl | Mean ± SD | 13.66 ± 9.89 | |
DAS-28 | Range (mean ± SD) | (2.9–6.2) 4.25 ± 0.99 | |
DAS-28 | Low | No (%) | 7 (13%) |
Moderate | 31 (62%) | ||
High | 12 (24%) | ||
RF-positive | No. (%) | 36/50 (72%) | |
RF titer u/ml | Median (IQR) | 16 (8–64) | |
Anti-CCP Abs-positive | No. (%) | 24/50 (48%) | |
Anti-CCP Abs titer u/ml | Median (IQR) | 20 (16.25–56) | |
Total MSUS score (0–36) | Median (IQR) | 8.5 (6–12) | |
US-SH score (0–18) | Median (IQR) | 6 (4–8) | |
US-PD score (0–18) | Median (IQR) | 2 (1–5) | |
Larsen score (0–100) | Median (IQR) | 16 (4.25–20) | |
Erosion in X-ray | No. of patients (%) | 17/50 (34%) | |
Erosion in US | No. of patients (%) | 23/50 (46%) |